Printed From:

Learn More About the SYNVISC® Family


EFFICACY

Rapid and long-lasting (up to 6 months) OA knee pain relief1-5

  • As early as 1 week compared with baseline in a pivotal study of SYNVISC (57.7 vs 69.7 on VAS, P=0.0001), determined by patient assessment3,a
  • Maintained at 6 months in pivotal studies of SYNVISC (35.7 vs 69.7 baseline on VAS, P=0.0001) and Synvisc-One® (1.43 vs 2.30 baseline on WOMAC A, P=0.047)3,4,a,b
  • At 12 months, a 44.8% reduction in pain from baseline was maintained with SYNVISC in a randomized, controlled, clinical trial versus Hyalgan5,c
  • Safety profiles of SYNVISC/Synvisc-One were similar to placebo1-4,a,b

View additional study details ›

See SYNVISC/Synvisc-One study details ›


EVIDENCE

In separate, head-to-head clinical trials, only the SYNVISC family of viscosupplements demonstrated superior OA knee pain relief versus all of the following: Saline Control1-4,a,b (P<0.05), Non-crosslinked sodium hyaluronate (Hyalgan)5,c (P=0.02), ICS (intra-articular corticosteroid) injection (triamcinolone hexacetonide)6,d.

View additional study details ›

See SYNVISC/Synvisc-One study details ›


SCIENCE

  • SYNVISC®/Synvisc-One® is the highest molecular weight HA available with a defined molecular weight1-2, 7-23,a
    • Only SYNVISC/Synvisc-One is composed of 2 unique formulations of crosslinked polymers, a fluid and a gel.15-19
  • SYNVISC®/Synvisc-One® is designed to stay in the knee joint longer than non-crosslinked viscosupplements1-2, 24-25,b
    • Crosslinking results in longer intra-articular residence times for SYNVISC/Synvisc-One (58 and 44 days, respectively, compared with <72 hours for unmodified hyaluronic acid products).26-27,b

a Among currently approved viscosupplements with a defined molecular weight.

The clinical significance of these physical properties is unknown. Comparisons cannot be made in absence of head-to-head clinical trials. This information is not based on any head-to-head clinical trial.


PATIENT SAFETY AND SATISFACTION

The SYNVISC family of viscosupplements has an established safety profile.5,6,9 81% patient satisfaction in a large observational clinical study to assess tolerability of SYNVISC28

of patients were satisfied with SYNVISC as their therapy, rating it as "good" or "very good", at 3 weeks after the first injection1

Tolerability was assessed by documenting the incidence and type of local AEs as well as severity and relation to therapy. Treatment AEs were reported in 4.2% of patients (2.4% of injections) and most were mild (21.4%) to moderate (40.3%)


EXPERIENCE

SYNVISC and Synvisc-One have been incuded in more than 300 publications and used to treat more than 15 million knees worldwide29


References

  1. SYNVISC [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
  2. Synvisc-One [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
  3. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410-423.
  4. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69(1):113-119.
  5. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee—a prospective randomized clinical trial. Knee. 2008;15(4):318-324.
  6. Caborn D, Rush J, Lanzer W, Parenti D, Murray C. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2):333-343.
  7. Gel-One [prescribing information]. Warsaw, IN: Zimmer USA; 2011.
  8. Monovisc summary of safety and effectiveness data. Silver Spring, MD: US Food and Drug Administration; 2014.
  9. Euflexxa [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; 2016.
  10. Orthovisc [prescribing information]. Raynham, MA: DePuy Mitek Inc; 2005.
  11. Hyalgan [prescribing information]. Parsippany, NJ: Fidia Pharma USA Inc; 2014.
  12. Supartz FX [prescribing information]. Durham, NC: Bioventus LLC; 2015.
  13. Hymovis [prescribing information]. Parsippany, NJ: Fidia Pharma USA Inc; 2015.
  14. GenVisc 850 [prescribing information]. Doylestown, PA: OrthogenRx Inc; 2015.
  15. Gelsyn-3 [prescribing information]. Pambio-Noranco, Switzerland: Institut Biochimique SA; 2016.
  16. Visco-3 [prescribing information]. Durham, NC: Bioventus LLC; 2016.
  17. Ågerup B, Berg P, Åkermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19(1):23-30.
  18. TriVisc [prescribing information]. Doylestown, PA: OrthogenRx Inc; 2017.
  19. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum. 1967;10(4):357-376.
  20. Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012;100(2):457-462.
  21. Balazs EA, Leshchiner A, Inventors; Biomatrix, Inc, Ridgefield, NJ, assignee. Cross-linked gels of hyaluronic acid and products containing such gels. US patent 4,582,865. April 15, 1986.
  22. Balazs EA, Leshchiner A, Leshchiner A, Band P, Inventors; Biomatrix, Inc, Ridgefield, NJ, assignee. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues. US patent 4,713,448. December 15, 1987.
  23. Sanofi. The Making of SYNVISC [video]. 2001.
  24. Bhuanantanondh P, Grecov D, Kwok E. Rheological study of viscosupplements and synovial fluid in patients with osteoarthritis. J Med Biol Eng. 2012;32(1):12-16.
  25. Henrotin Y, Raman R, Richette P, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum. 2015;45(2):140-149
  26. Data on file. Genzyme Corporation.
  27. Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012;100(2):457-462.
  28. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269.
  29. IMS sales data, 2017.

MySynviscONE®

Visit the MySynviscONE® section of the site for details and more.

Visit  MySynviscONE® to learn more about benefits.
View Page ›

SAUS.HYL.17.10.8155f(1)

Order Synvisc-One® and SYNVISC®

Learn about the different ordering options and how to get next-day delivery with your MySynviscONE® account.

Order now ›

SAUS.HYL.17.10.8155f(1)

Resources for
Your Patients

Share these tools to help patients get the most out of their treatment.

Resources for your patients
Browse Resources ›

SAUS.HYL.17.10.8155f(1)